Sandoz responds to Amgen in Zarxio case

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) filed an opposition brief to a motion by Amgen Inc. (NASDAQ:AMGN) seeking a preliminary injunction pending appeal that would prevent Sandoz from launching Zarxio filgrastim-sndz. The biosimilar of Amgen's Neupogen filgrastim is the first approved biosimilar product in the U.S. Sandoz filed the brief with the U.S. District Court for the Northern District of California.

Sandoz said Amgen's motion fails to meet standards for granting a preliminary injunction and that no oral argument should be needed to deny the motion because Amgen "simply repeats arguments that this Court already rejected after a full brieing and argument." ...